Systemic Sclerosis

Criteria to qualify for study: Drug used in study:
  • Patients unwilling or unable to discontinue DMARDs for treatment of SSc at time of randomization will be excluded.
  • Patients with a history or presence of a 2nd autoimmune disease requiring immunosuppressive therapy will be excluded

FHCRC 2533 - CBCI-224

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis

On Hold


Central Peripheral Nervous System

Criteria to qualify for study: Drug used in study:
  • Patients must have failed at least 2 lines of standard therapy.
  • Patients with evidence of myelodysplasia will be excluded

FHCRC 2260 CBCI-232

High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Disease